Physician profile
Marcus A Wing
NPI 1487041497
$1,487.32
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $24.11 · 2021: $190 · 2022: $221 · 2023: $665 · 2024: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.99 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $175.00 | 2019-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $135.45 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $102.06 | 2019-2023 | |
| Lilly USA, LLC | $92.28 | 2022-2023 | Mounjaro, Emgality, Jardiance |
| Glaxosmithkline, LLC. | $91.63 | 2021-2024 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $63.00 | 2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $51.21 | 2019 | |
| Dexcom, INC. | $38.23 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $22.53 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $21.23 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $20.79 | 2022 | |
| Lucid Diagnostics INC. | $19.67 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2022 | |
| Eisai INC. | $17.53 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.50 | 2019 | |
| Horizon Therapeutics Plc | $15.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2024 | |
| Merck Sharp & Dohme LLC | $14.71 | 2023 | Pneumovax 23, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.45 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Wing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.